Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting | withdrawn | — | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07614828 | Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa | withdrawn | Phase 2 | 0 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 10, 2026 |
| clinicaltrials |
| NCT07092410 | Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib(SuRage-EB) | withdrawn | Phase 4 | 0 | SRH Wald-Klinikum Gera GmbHOTHER | 0 | Apr 21, 2026 | clinicaltrials |
| NCT04129515 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Brown UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06508827 | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | withdrawn | Phase 1 | 0 | James Isaacs, MDOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | withdrawn | Phase 2 | 0 | BiogenINDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT02145910 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT03448666 | ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | withdrawn | Phase 2 | 0 | European Institute of OncologyOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03989050 | Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors(SPICE) | withdrawn | — | 0 | University of CologneOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | withdrawn | Phase 2 | 0 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | withdrawn | Phase 2 | 0 | Multidisciplinary Association for Psychedelic StudiesOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05299580 | "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" | withdrawn | Phase 2 | 0 | Fondazione Melanoma OnlusOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 18, 2023 | clinicaltrials |
| NCT05561491 | A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | withdrawn | Phase 2 | 0 | Targovax OyINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04703426 | Sargramostim (GM-CSF) + PD-1 | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 22, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | withdrawn | Phase 1 | 0 | Pierre Fabre MedicamentINDUSTRY | 3 | Feb 21, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT02473874 | Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy | withdrawn | — | 0 | University of California, IrvineOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03754140 | Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases(INTRANS) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT02854488 | Yervoy Pregnancy Surveillance Study | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01930968 | Definity for Ultrasound of Intraocular Tumors | withdrawn | — | 0 | Emory UniversityOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04223648 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | withdrawn | Early Phase 1 | 0 | Yale UniversityOTHER | 0 | Nov 22, 2021 | clinicaltrials |
| NCT04995094 | Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | withdrawn | Phase 2 | 0 | HiberCell, Inc.INDUSTRY | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | withdrawn | Phase 1 | 0 | Nektar TherapeuticsINDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)(CINDI) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04042506 | SBRT as a Vaccination for Metastatic Melanoma | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT04495010 | Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants(CheckMate 7UA) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 16 | Mar 19, 2021 | clinicaltrials |
| NCT03758729 | Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. | withdrawn | Phase 2 | 0 | Samsung Medical CenterOTHER | 0 | Feb 16, 2021 | clinicaltrials |
| NCT03972046 | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | withdrawn | Phase 2 | 0 | TriHealth Inc.OTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03126461 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01826864 | Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | withdrawn | Phase 3 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02263898 | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04285749 | Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT04184518 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma(CEDUVEAL-M) | withdrawn | Phase 2 | 0 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Jun 2, 2020 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials